Tag Archive for: ALS

Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company

/in

– New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism – Deal worth up to $415m including upfront and downstream, plus royalties on top – ATLX-1282 is the first programme out of Alchemab’s entirely novel platform which generates and analyses millions of antibody sequences […]

Read more

Alchemab Therapeutics enters into collaboration with Lilly to discover, research and develop novel therapies for ALS

/in

Agreement supports the research and development of up to five novel therapeutic antibodies identified through Alchemab’s antibody discovery platform. Cambridge, UK, 9 January 2025 – Alchemab Therapeutics (Alchemab), a biopharmaceutical company aiming to identify and develop naturally occurring therapeutic antibodies from resilient individuals, today announces it has entered a collaboration with Lilly to discover novel […]

Read more